



## Spotlight On: Etanercept

## VENABLE | Fitzpatrick

Sep. 30, 2021

**Technology:** Etanercept is a recombinant tumor necrosis factor receptor ("TNFR"):F<sub>c</sub> fusion protein that is indicated for the treatment of various types of arthritis, ankylosing spondylitis, and plaque psoriasis.





|           | Sandoz v. Amgen<br>3:13-cv-02904 (N.D.<br>Cal.) Dismissed for lack<br>of subject matter<br>jurisdiction; Fed. Cir.<br>14-1693 Affirmed | Amgen v. Sandoz 2:16-cv-01118 (D.N.J.) Patents not invalid; Stipulation of infringement; Appeal 20-1037 Affirmed, Request for en banc rehearing denied; Supreme Court 20-1110 Certiorari denied | Amgen v. Samsung<br>Bioepis 2:19-cv-11755<br>(D.N.J.)<br>Ongoing | Coalition for Affordable<br>Drugs v. Amgen<br>IPR2015-01792<br>Institution denied | Coherus v. Hoffman-La<br>Roche<br>IPR2017-01916<br>Institution denied | Coherus v. Hoffman-La<br>Roche<br>IPR2017-02066<br>Institution denied |
|-----------|--|---|--|---|---|---|
| 7,915,225 |  | X   | X  |   |   |   |
| 8,063,182 | x  | x   | x  |   |   | x   |
| 8,119,605 |  | x   | x  |   |   |   |
| 8,163,522 | x  | x   | x  | x   | x   |   |
| 8,722,631 |  | x   | x  |   |   |   |